Abbassi A F, Said A, Gaber A
Department of Gynaecology and Obstetrics, Faculty of Medicine, Cairo University, Egypt.
J Int Med Res. 1991;19 Suppl 1:44A-49A.
Estimates were carried out on the clinical and bacteriological efficacy of an intramuscular combination of sulbactam/ampicillin, together with an assessment of its tolerability and safety in the treatment of gynaecological and obstetric infections. A total of 30 women with pelvic inflammatory disease, wound infections, vaginitis and puerperal sepsis received an intramuscular combination of sulbactam/ampicillin in a total daily dose of 1.5 g for between 3 and 7 days. Clinical cure and improvement were achieved in 27 (90%) cases but there was no response in three (10%) cases. No side-effects were seen in 29 (97%) cases, whereas tolerable local injection site pain was reported in one case. The safety of the sulbactam/ampicillin antibiotic combination was evident in all the cases studied, as there was no significant difference between the means of laboratory tests before and after therapy of blood and renal measures.
对舒巴坦/氨苄西林肌肉注射联合用药的临床和细菌学疗效进行了评估,并对其在治疗妇产科感染中的耐受性和安全性进行了评价。共有30例患有盆腔炎、伤口感染、阴道炎和产褥期败血症的女性接受了舒巴坦/氨苄西林肌肉注射联合治疗,日总剂量为1.5g,疗程3至7天。27例(90%)患者实现了临床治愈和病情改善,但3例(10%)患者无反应。29例(97%)患者未出现副作用,而有1例报告了可耐受的局部注射部位疼痛。在所有研究病例中,舒巴坦/氨苄西林抗生素联合用药的安全性明显,因为治疗前后血液和肾脏指标的实验室检测均值之间没有显著差异。